Seeking Alpha

A year after Lipitor lost its patent protection, a number companies are making headway on the...

A year after Lipitor lost its patent protection, a number companies are making headway on the next generation of medicines for reducing LDL, or "bad cholesterol." Much interest focuses on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (AMGN) (see [[here]]) and Pfizer (PFE) yesterday presenting data showing that their drugs performed well in mid-stage trials. Sanofi (SNY) and partner Regeneron (REGN) announced a massive Phase III trial for their treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)